Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02584140 · ClinicalTrials.gov registry record · Phase 4
Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 136
- Enrollment target
NCT02584140 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 136 participants.
The verdict
NCT02584140, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to test a program that uses drug level monitoring, text messaging ("iTAB") and personalized counseling with HIV prevention services, including PrEP (medicine that can help prevent HIV infection when taken daily).
Interventions
- BEHAVIORAL Text Messaging
- BEHAVIORAL Adherence Counseling
- DRUG Daily Oral PrEP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2016-05 |
| Est. Completion | 2019-06-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02584140
The ClinicalTrials.gov registry entry for NCT02584140 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Text Messaging is the first listed.
NCT02584140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02584140 about?
NCT02584140 is a clinical study titled "Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women". The purpose of this study is to test a program that uses drug level monitoring, text messaging ("iTAB") and personalized counseling with HIV prevention services, including PrEP (medicine that can help prevent HIV infection when taken daily).
What is the current status of trial NCT02584140?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 136 participants. The study started on 2016-05. Estimated completion is 2019-06-14.
What interventions are being tested in trial NCT02584140?
The interventions under investigation include: Text Messaging (BEHAVIORAL), Adherence Counseling (BEHAVIORAL), Daily Oral PrEP (DRUG).
Who is sponsoring clinical trial NCT02584140?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.